Claude’s Protein Binder Experiment Points to a New R&D Operating Model

TL;DR

Claude designed wet-lab-confirmed protein binders against 14 of the 15 targets that produced interpretable results. This ran on a roughly 30,000 token human protocol and up to 12,500 H100 hours of compute. I see this as a glimpse of a different R&D operating model: a general-purpose AI coordinating specialist models, compute and labs. This is a smarter position for Anthropic than carrying molecules through the clinic.

I didn't want my feed to become an Anthropic news cycle. But a day after I challenged Dario Amodei's cure timeline, Anthropic published results backing the other half of my argument: they are becoming the intelligence layer of drug discovery.

Here's what happened: Claude "designed" wet-lab-confirmed protein binders against 14 of the 15 targets that produced interpretable results.

What Claude designed actually means

Now, what does "Claude designed" actually mean? A human expert encoded the process in a protocol of roughly 30,000 tokens. Two thirds of it dealt with orchestration, verification and operations. The 48-hour campaign ran on up to 12,500 H100 hours of compute.

Claude then installed and validated the available open-source protein models, chose where on each target to bind, assembled a different combination of tools for each target, ran the optimization cycles and selected which designs should be made. Two external labs, Adaptyv Bio and Twist Bioscience, built and tested the proteins.

This is a glimpse of a different R&D operating model: human expertise encoded into a repeatable protocol, with a general-purpose AI coordinating specialist models, compute and the labs that test the output.

The results also show how early this is. Performance varied considerably between targets and campaigns. Opus 4.8 succeeded against TNFα while the generally more capable Mythos Preview failed. Anthropic could not say whether the difference came from the model, the pipeline it chose or ordinary variation between runs.

How early this still is

And obviously, binding is also only the very beginning. Function, safety, dosing, manufacturing and clinical benefit all remain ahead.

Anthropic released the designs and experimental results, including the failures, creating a public benchmark for future protein-design systems.

On Tuesday, I wrote: "As the intelligence layer, Anthropic can work on thousands of programs without carrying a single asset on its balance sheet." This is a much smarter position for Anthropic than becoming one more company carrying molecules through the clinic.